Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Rapport Therapeutics, Inc.. The associated price target remains the same with $42.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Justin Walsh has given his Buy rating due to a combination of factors surrounding Rapport Therapeutics, Inc. A significant reason for this rating is the anticipated topline data readout from the Phase IIa trial of RAP-219 in refractory focal epilepsy, expected in September 2025. This event is seen as a crucial milestone that could validate the clinical efficacy of RAP-219, potentially increasing interest and momentum for the company.
Additionally, the company’s focus on RAP technology and biomarker-informed trial design is expected to create a robust pipeline, offering long-term value for shareholders. The current landscape of focal epilepsy treatment presents unmet needs, and Rapport Therapeutics is positioned to address these with its innovative approach. The company’s financial health, evidenced by its cash reserves, further supports the positive outlook and the Buy rating.
In another report released on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $31.00 price target.